-
Experts warn that recent US funding cuts to PEPFAR could lead to increased HIV drug resistance, jeopardizing treatment for millions. The lack of access to antiretroviral drugs, particularly dolutegravir, raises concerns about the future of HIV management in low and middle-income countries.
-
Antimicrobial resistance (AMR) is increasingly recognized as a global health threat, with experts warning of its rising impact on public health. Recent studies highlight the urgent need for awareness and action, particularly in low-income countries where access to effective treatments is severely limited. The situation is exacerbated by the misuse of antibiotics and antifungals in healthcare and agriculture.
-
South Africa's HIV treatment efforts are jeopardized by significant funding cuts from the U.S. government, which have led to the closure of specialized clinics and job losses among health workers. Health Minister Aaron Motsoaledi warns of severe impacts on patient care and treatment access for vulnerable populations.
-
In Lesotho, rising crystal meth use and dangerous practices like 'bluetoothing' are alarming parents and health officials. Meanwhile, cuts to US HIV funding are exacerbating health crises in Uganda and Malawi, where access to lifesaving medication is severely limited. The situation poses significant risks to vulnerable populations across the region.
-
The FDA has approved the first at-home cervical cancer test, expanding self-administered testing options. However, experts caution that these tests cannot replace in-person medical evaluations. Meanwhile, quality issues with a prostate cancer testing kit from Abbott Laboratories have raised concerns in Hong Kong, prompting follow-up actions by health authorities.
-
Experts warn that potential cuts to UK funding for Gavi, a global vaccination alliance, could undermine efforts to combat infectious diseases and lead to avoidable child deaths. The UK has historically been a major contributor, but funding is uncertain amid budget reductions.
-
Australian researchers have developed a novel lipid nanoparticle that delivers mRNA to HIV-infected cells, potentially revealing hidden virus reservoirs. This advancement could pave the way for a cure, as it allows the immune system to target the virus more effectively. The findings were published in Nature Communications.
-
The FDA has approved lenacapavir, a groundbreaking HIV prevention drug offering six-month protection with just two injections. While it shows promise in reducing infections, challenges remain regarding accessibility and funding, particularly in the U.S. and globally. Experts warn that systemic healthcare issues could hinder its rollout.